Markets:

Overview

News

Currencies

International

Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

78.55 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? ↗

June 11, 2024

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.

Via The Motley Fool

Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗

June 10, 2024

The company is focusing on obesity treatment after its glaucoma drug failed.

Via Investor's Business Daily

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? ↗

June 09, 2024

Structure Therapeutics has a long way to go before beating Wegovy.

Via The Motley Fool

Top Names Performance Update - Saturday, June 8 ↗

June 08, 2024

I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone...

Via Talk Markets

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says ↗

June 03, 2024

Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target

Via Benzinga

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 03, 2024

Via Benzinga

Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results ↗

June 03, 2024

Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 03, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 03, 2024

Via Benzinga

Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate ↗

June 03, 2024

Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 03, 2024

Via Benzinga

Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing ↗

May 31, 2024

Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.

Via InvestorPlace

This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan ↗

May 21, 2024

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.

Via Benzinga

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024 ↗

May 09, 2024

GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025 ↗

May 09, 2024

The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.

Via InvestorPlace

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains ↗

April 24, 2024

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

Via InvestorPlace

7 Small-Cap Stocks that Wall Street Loves for Good Reason ↗

March 30, 2024

As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves.

Via InvestorPlace

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023 ↗

March 15, 2024

GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

The Best-Performing U.S. IPOs Of 2023 ↗

February 04, 2024

In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year.

Via Talk Markets

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now ↗

December 25, 2023

It has genuine struggles ahead, but it has some actual value in hand as well.

Via The Motley Fool

7 Small-Cap Stocks That Wall Street Loves for Good Reason ↗

December 22, 2023

The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading

Via InvestorPlace

Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗

December 22, 2023

Despite a Wednesday tumble, the major indexes are right at 2023 highs.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 19, 2023

Via Benzinga

Nasdaq Gains 100 Points; Biomerica Shares Spike Higher ↗

December 18, 2023

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07....

Via Benzinga

Topics Stocks

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 18, 2023

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 18, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

Headline News about Structure Therapeutics Inc. - American Depositary Shares

Starting at $3.75/week.

Subscribe Today